Pentrys

Pentrys is a biotechnology company focused on the discovery and development of small molecule inhibitors for the classical complement pathway. A spinout from the University of Oxford, the company leverages deep expertise in structural biology to target the C1 complex, a key initiator of the complement cascade. Pentrys aims to provide oral therapeutic alternatives to existing injectable complement therapies for patients suffering from autoimmune and inflammatory conditions. The company's lead programs are currently in the pre-clinical stage, focusing on high-potency molecules with favorable drug-like properties. Pentrys is backed by Oxford Science Enterprises and is headquartered in the United Kingdom.